Vagal Nerve Stimulation and Glucose Metabolism

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Adrian Vella, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01117311
First received: May 4, 2010
Last updated: January 18, 2013
Last verified: January 2013
  Purpose

The overall aim of this application is to determine the mechanism(s) by which common bariatric surgical procedures alter carbohydrate metabolism. The study proposed will examine the effect of vagal nerve stimulation on insulin secretion and action.


Condition Intervention
Type 2 Diabetes
Obesity
Gastric Emptying
Device: VNS on
Device: VNS off

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Disposition Index [ Time Frame: Compared to VNS on or off ] [ Designated as safety issue: No ]
    The appropriateness of insulin secretion for the prevailing degree of insulin action is assessed by calculating the total disposition index (DItotal), which equals the product of insulin secretion and insulin sensitivity.


Secondary Outcome Measures:
  • Gastric Emptying [ Time Frame: Compared to VNS on or off ] [ Designated as safety issue: No ]
    Gastric emtpying will be measured by anterior and posterior gamma camera images obtained immediately after meal ingestion, every 15 minutes for the first 2 hours, then every 30 minutes for the next 2 hours (total 4 hours after the meal) for gastric emptying measurements


Enrollment: 9
Study Start Date: March 2011
Study Completion Date: November 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: VNS off
Vagal nerve stimulator off at time of study
Device: VNS off
The implanted Vagal Nerve Stimulator will be off at the time of study
Active Comparator: VNS on
Vagal nerve stimulator on at the time of study
Device: VNS on
The implanted vagal nerve stimulator will be on

Detailed Description:

The overall aim of this application is to determine the mechanism(s) by which common bariatric surgical procedures alter carbohydrate metabolism. Very often, resolution of diabetes occurs in the early post-operative period prior to the development of significant weight loss. It has been suggested that bariatric surgery alters insulin action but few studies have examined insulin secretion or postprandial glucose fluxes in such patients. At the present time, little is known about how the various bariatric surgical procedures alter glucose homeostasis. It is essential that the effect of bariatric surgery and meal size on these parameters be understood and accurately measured. Enteroendocrine secretion is affected by the rate of intestinal delivery of calories and may also be modulated by the enteric nervous system and the rate of direct delivery of nutrients to enteroendocrine cells. Direct measurement of intestinal transit is also an important part of understanding how bariatric surgery alters intestinal secretion of hormones that may alter glucose metabolism. The Oral and C-peptide Minimal Models when applied to C-peptide, glucose and insulin concentrations after ingestion of a standard labeled mixed meal can accurately measure insulin secretion and action. Subsequently, the disposition index provides a measurement of the appropriateness of insulin secretion for the prevailing insulin action. When coupled with established triple-tracer methodology, a mixed meal can be used to measure fasting and postprandial glucose fluxes. Though the vagal trunks are preserved during bariatric surgery, gastric transection during the formation of a gastric pouch for RYGB, or during the sleeve gastrectomy for the duodenal switch procedure, may denervate post-gastric organs including the pancreas and intestine. Reversible vagal block results in weight loss, decreased caloric intake, earlier satiation and reduced hunger. The effect of this form of vagal denervation on glycemic control is unclear. There is evidence that hepatic parasympathetic input regulates insulin action in rodents. Vagal afferents are also important in hepatoportal glucose sensing.

  Eligibility

Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Type 2 Diabetes Previous Implantation of a Vagal Nerve Stimulator for obesity

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01117311

Locations
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Adrian Vella, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Adrian Vella, Professor of Medicine, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01117311     History of Changes
Other Study ID Numbers: 09-008825
Study First Received: May 4, 2010
Last Updated: January 18, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Vagus
Diabetes
Obesity

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Obesity
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on June 17, 2013